Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3682937 | 0.81 | PPARD (0.44) | PPARD | |
| SCHEMBL3681587 | 0.80 | PPARD (0.42) | PPARDKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL13508291 | 0.80 | PPARD (0.42) | PPARDKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL23216392 | 0.63 | EPHX2 (0.55) | EPHX2KMT2AMEN1KDM4EPPARG | |
| SCHEMBL1560218 | 0.63 | KMT2A (0.48) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL3680963 | 0.60 | DNM1 (0.59) | KMT2AMEN1ALDH1A1ANPEPERAP2 | |
| SCHEMBL26618636 | 0.60 | DNM1 (0.59) | KMT2AMEN1ALDH1A1ANPEPERAP2 | |
| SCHEMBL16839637 | 0.59 | EPHX2 (0.55) | EPHX2PPARDPPARG | |
| SCHEMBL11495749 | 0.59 | KMT2A (0.47) | EPHX2KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL28896240 | 0.58 | KDM4E (0.54) | EPHX2KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | EPHX2 2291/4885PPARD 1/4885KMT2A 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.